The Secret Life of Translation Initiation in Prostate Cancer
- 1Unit of Biomedical Research on Cancer, Instituto Nacional de Cancerología (INCan), Mexico
Prostate cancer (PCa) is the second most prevalent cancer in men worldwide. Despite the advances understanding the molecular processes driving the onset and progression of this disease, as well as the continued implementation of screening programs, PCa still remains a significant cause of morbidity and mortality, in particular in low-income countries. It is only recently that defects of the translation process, i.e. the synthesis of proteins by the ribosome using a messenger (m)RNA as a template, have begun to gain attention as an important cause of cancer development in different human tissues, including prostate. In particular, the initiation step of translation has been established to play a key role in tumorigenesis. In this review, we discuss the state-of-the-art of three key aspects of protein synthesis in PCa, namely misexpression of translation initiation factors, dysregulation of the major signaling cascades regulating translation, and the therapeutic strategies based on pharmacological compounds targeting translation as a novel alternative to those based on hormones controlling the androgen receptor pathway.
Keywords: Prostate cancer (PC), translation initiation, translational control, Androgen Receptor (AR), eIF4E, mTOR (« mammalian target of rapamycin »), MAPK (Mitogen-activated protein kinase), prostate cancer, eIF4G
Received: 12 Aug 2018;
Accepted: 11 Jan 2019.
Edited by:Chiara Gamberi, Concordia University, Canada
Reviewed by:Woan-Yuh Tarn, Academia Sinica, Taiwan
Hari K. Koul, Louisiana State University Health Sciences Center Shreveport, United States
Copyright: © 2019 Hernández, Pedroza-Torres, Ramírez, Herrera and Jiménez-Ríos. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence: Dr. Greco Hernández, Instituto Nacional de Cancerología (INCan), Unit of Biomedical Research on Cancer, Mexico, Mexico, email@example.com